Meeting News

NuSight launches at-home dry eye treatment device

DENVER – NuSight Medical launched the NuLids System, a doctor-prescribed, home-use medical device for treating dry eye, here at Optometry’s Meeting.

The system is designed to clean the biofilm on the lids and stimulate the meibomian glands, NuSight President and CEO Rob Foster told Primary Care Optometry News.

“By gently stimulating, de-capping and rejuvenating the meibomian glands to a healthier state, NuLids improves dry eye clinical signs and symptoms,” the company said in a press release.

“We postulate that it improves capillary perfusion, taking toxins away from the cells and stimulating the meibomian glands,” Foster told PCON.

A recent multicenter clinical study showed that the use of the NuLids System was associated with a 65% improvement in tear break-up time and an 81% improvement in meibomian glands yielding liquid secretions, according to the press release. In addition, the majority of patients reported a twofold improvement in their dry eye symptoms after only 2 weeks of daily use.

NuLids takes 60 seconds per day to use, and clinical studies showed that 95% of patients surveyed after a 30-d ay trial reported being “satisfied” or “very satisfied” with the treatment.

NuLids is sold only through eye care practitioners, the company said in the release.

“Doctors are in control of the therapy, while patients perform the treatment at home, improving practice efficiency,” Foster said in the release. – by Nancy Hemphill, ELS, FAAO

Disclosure: Foster is employed by NuSight Medical.

DENVER – NuSight Medical launched the NuLids System, a doctor-prescribed, home-use medical device for treating dry eye, here at Optometry’s Meeting.

The system is designed to clean the biofilm on the lids and stimulate the meibomian glands, NuSight President and CEO Rob Foster told Primary Care Optometry News.

“By gently stimulating, de-capping and rejuvenating the meibomian glands to a healthier state, NuLids improves dry eye clinical signs and symptoms,” the company said in a press release.

“We postulate that it improves capillary perfusion, taking toxins away from the cells and stimulating the meibomian glands,” Foster told PCON.

A recent multicenter clinical study showed that the use of the NuLids System was associated with a 65% improvement in tear break-up time and an 81% improvement in meibomian glands yielding liquid secretions, according to the press release. In addition, the majority of patients reported a twofold improvement in their dry eye symptoms after only 2 weeks of daily use.

NuLids takes 60 seconds per day to use, and clinical studies showed that 95% of patients surveyed after a 30-d ay trial reported being “satisfied” or “very satisfied” with the treatment.

NuLids is sold only through eye care practitioners, the company said in the release.

“Doctors are in control of the therapy, while patients perform the treatment at home, improving practice efficiency,” Foster said in the release. – by Nancy Hemphill, ELS, FAAO

Disclosure: Foster is employed by NuSight Medical.

    See more from Optometry's Meeting